AMAryana Malanova

Aryana Malanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aryana Malanova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical significance of assessing right ventricular metabolism and perfusion using positron emission tomography combined with computed tomography in patients with pulmonary arterial hypertension: a literature review

    by A. S. Malanova, N. S. Goncharova, D. V. Ryzhkova

    Pulmonary arterial hypertension (PAH) is a hemodynamic and pathophysiological condition associated with high mortality due to right ventricular (RV) heart failure. Modern diagnostic methods confirm the already existing RV remodeling and dysfunction. The search for non-invasive diagnostic methods that can detect early signs of RV myocardial dysadaptation is critical for adequate mortality risk stratification and assessing the effect of therapy to select the optimal management stra­tegy and improve prognosis in patients with PAH. This review focuses on positron emission tomography combined with computed tomography (PET/CT) in patients with PAH. PET/CT makes it possible to analyze disease mechanisms at the level of tissue metabolism and perfusion, which is not possible with traditional diagnostic methods. PET/CT may eventually become an important tool in search for new therapeutic targets and a personalized approach to treating patients with PAH.

  • Open Access

    PET/CT Imaging of the Right Heart Perfusion and Glucose Metabolism Depending on a Risk Status in Patients With Idiopathic Pulmonary Arterial Hypertension

    by Natalia Goncharova, Daria Ryzhkova, Kirill Lapshin, Anton Ryzhkov, Aryana Malanova, Elizaveta Andreeva, Olga Moiseeva

    Right ventricular heart failure (RV HF) is the leading cause of death in pulmonary arterial hypertension (PAH). Relevance of the low‐risk status assessment using available diagnostic tools requires a reliable confirmation. The study aimed to evaluate right ventricular perfusion and glucose metabolism using positron emission tomography (PET)/computed tomography (CT) with [13N]‐ammonia and [18F]‐fluorodeoxyglucose ([18F]‐FDG) in 30 IPAH patients (33.8 ± 9.4 years) according to ESC/ERS 2022 risk status. The ratio of SUVmaxRV/LV metabolism and SUVmaxRV/LV perfusion showed significant positive correlation with pulmonary artery pressure, right heart dilatation, NT‐proBNP level and negative correlation with the RV ejection fraction. The SUVmaxRV/LV perfusion and SUVmaxRV/LV metabolism ratios differed significantly according to risk status. Low risk patients had a SUVmaxRV/LV metabolism comparable to the controls without PH. The SUVmaxRV/LV perfusion ratio was elevated in low‐risk IPAH patients compared with controls. Increased SUVmaxRV/LV perfusion may be an early marker of coronary flow adaptation to RV pressure overload in low‐risk IPAH patients and requires further evaluation. Further long‐term studies are needed to determine the clinical relevance and cut‐off values for the RV/LV PET/CT with [13N]‐ammonia and [18F]‐fluorodeoxyglucose ([18F]‐FDG) uptake in different IPAH risk groups.